Kera Capital Partners Inc. cut its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) by 68.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,603 shares of the company’s stock after selling 289,321 shares during the period. Kera Capital Partners Inc. owned approximately 0.30% of Kyverna Therapeutics worth $1,246,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of KYTX. Adage Capital Partners GP L.L.C. purchased a new position in Kyverna Therapeutics in the 4th quarter worth about $15,667,000. AIGH Capital Management LLC purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $14,100,000. Balyasny Asset Management L.P. purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $9,220,000. Propel Bio Management LLC acquired a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $6,267,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $5,640,000. Institutional investors and hedge funds own 18.08% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on KYTX shares. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. reduced their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.
Kyverna Therapeutics Stock Up 0.4%
Shares of Kyverna Therapeutics stock opened at $8.07 on Friday. The stock has a 50-day moving average price of $8.91 and a 200 day moving average price of $8.56. The company has a market cap of $490.58 million, a P/E ratio of -2.46 and a beta of 1.95. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. Kyverna Therapeutics, Inc. has a 1 year low of $2.52 and a 1 year high of $13.67.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. As a group, analysts expect that Kyverna Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.
Kyverna Therapeutics Company Profile
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Featured Stories
- Five stocks we like better than Kyverna Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report).
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
